Mukamal Kenneth J, Clowry Catherine M, Murray Margaret M, Hendriks Henk F J, Rimm Eric B, Sink Kaycee M, Adebamowo Clement A, Dragsted Lars O, Lapinski P Scott, Lazo Mariana, Krystal John H
Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
National Institute on Alcohol Abuse and Alcoholism, Rockville, Maryland.
Alcohol Clin Exp Res. 2016 Nov;40(11):2283-2291. doi: 10.1111/acer.13231. Epub 2016 Sep 30.
Drinking within recommended limits is highly prevalent in much of the world, and strong epidemiological associations exist between moderate alcohol consumption and risk of several major chronic diseases, including coronary heart disease, diabetes, and breast cancer. In many cases, plausible biological mediators for these associations have been identified in randomized trials, but gold standard evidence that moderate drinking causes or prevents any chronic disease remains elusive and important concerns about available evidence have been raised. Although long-term randomized trials to test the observed associations have been termed impossible, clinical investigators have now successfully completed randomized trials of complex nutritional interventions in a variety of settings, along with trials of alcohol consumption itself of up to 2 years duration. The successful completion of these trials suggests that objections to the execution of a full-scale, long-term clinical trial of moderate drinking on chronic disease are increasingly untenable. We present potential lessons learned for such a trial and discuss key features to maximize its feasibility and value.
在世界上许多地区,按推荐限度饮酒的情况非常普遍,而且适度饮酒与包括冠心病、糖尿病和乳腺癌在内的几种主要慢性病风险之间存在很强的流行病学关联。在许多情况下,随机试验已经确定了这些关联的合理生物学介质,但适度饮酒导致或预防任何慢性病的金标准证据仍然难以捉摸,并且人们对现有证据提出了重要担忧。尽管长期随机试验来检验观察到的关联被认为是不可能的,但临床研究人员现在已经在各种环境中成功完成了复杂营养干预的随机试验,以及长达2年的饮酒本身的试验。这些试验的成功完成表明,反对对慢性病进行适度饮酒的全面、长期临床试验的理由越来越站不住脚。我们介绍了此类试验可能吸取的经验教训,并讨论了使其可行性和价值最大化的关键特征。